AKT1 and triple-negative breast carcinoma: A novel C-terminal domain Hsp90 inhibitor, SL-145, effectively suppressed metastatic triple-negative breast cancers by inhibiting oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling, and without an induction of the heat shock response [106].